Clinical trials: cGVHD
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
cGVHD
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
- Trial name
- THRIVE (NCT05919511)
- Testing
- Non-Interventional
- Where
- 37 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Incyte Corporation
cGVHD
Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)
Chronic graft-versus-host disease (cGvHD) is a serious condition that can happen after a stem cell or bone marrow transplant. The donor's immune cells attack the patient's body, causing inflammation, pain, and damage to organs…
- Trial name
- BELRUX (NCT07643025)
- Testing
- Belumosudil, Ruxolitinib
- Where
- Canada
- Volunteers
- 53 people
- Sponsor
- Dennis Kim
cGVHD
Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD
This is a randomized, single-center phase 1/2 clinical trial without blinding. Iguratimod, as a rheumatoid arthritis medication, is used to treat autoimmune diseases such as Sjögren's syndrome.
- Trial name
- NCT06244628
- Testing
- Iguratimod
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Xuzhou Medical University
Chronic Graft vs. Host Disease, GVHD
Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is a condition that can develop after a stem cell transplant. It occurs when donor immune cells attack the body's tissues.
- Conditions
- Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
- Trial name
- NCT07728708
- Testing
- Axatilimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Hematopoietic Stem Cell Transplantation (HSCT), cGVHD
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD
This prospective, randomized, open-label, multicenter trial aims to compare second-line treatment strategies for hepatic cGVHD after allo-HSCT.
- Conditions
- Hematopoietic Stem Cell Transplantation (HSCT), cGVHD, Hepatic cGVHD, Belumosudil
- Trial name
- NCT07794514
- Testing
- Ruxolitinib treatment, Belumosudil treatment, Belumosudil Switch to Ruxolitinib
- Where
- China
- Volunteers
- 170 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Graft -Versus-host-disease, aGVHD
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD
- Trial name
- NCT07246031
- Testing
- BPC-2001
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- BioPhoenix Co., Ltd.
cGVHD
IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD
A single-center, Phase 1, open-label, investigator-initiated clinical trial evaluating the safety, tolerability, and preliminary efficacy of sarilumab (anti-IL-6R) monotherapy as a rescue in adult patients with…
- Trial name
- NCT07484113
- Testing
- Belumosudil, Sarilumab
- Volunteers
- 10 people
- Sponsor
- Stanford University
Chronic Graft-versus-host Disease (cGVHD)
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has failed 1-2 prior lines of…
- Trial name
- NCT06660355
- Testing
- Ruxolitinib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 120 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Graft Versus Host Disease (cGvHD)
Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
Hematopoietic Stem Cell Transplant (HCT) has been used to treat children and adults who have leukemia, lymphoma and other cancers of blood and immune cells since the 1970s. For many of these forms of cancer, HCT works well.
- Trial name
- EVENT (NCT06991361)
- Testing
- EVE-Treg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Leslie Kean
Chronic Graft Versus Host Disease, cGVHD
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).
- Trial name
- NCT06663722
- Testing
- Axatilimab, Extracorporeal Photopheresis
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of Miami
cGVHD
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
The study plan aims to include patients who have been diagnosed with steroid-refractory chronic GVHD in the liver following allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT06364319
- Testing
- anti-CD25 rhMAb, Prednisone, Ruxolitinib
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
cGVHD
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).
- Trial name
- NCT07253259
- Testing
- GT729 Injection
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Grit Biotechnology
Chronic Graft-versus-host Disease, Chronic GVHD
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease
This research study is evaluating the feasibility and acceptability of implementing a telehealth palliative care intervention in patients with moderate to severe chronic graft-versus-host disease.
- Conditions
- Chronic Graft-versus-host Disease, Chronic GVHD, cGVHD
- Trial name
- cGVHDTele-PC (NCT06458127)
- Testing
- Tele-palliative care visit
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
cGVHD, HSCT
Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).
This study aims to evaluate the safety and efficacy of Gecacitinib in patients with steroid-refractory/dependent active chronic graft versus host disease (cGVHD).
- Trial name
- CONTINUUM-GVHD (NCT07476872)
- Testing
- Gecacitinib
- Volunteers
- 33 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Graft-Versus-Host Disease (cGVHD)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD.
- Trial name
- NCT06619561
- Testing
- Vimseltinib
- Where
- 26 sites in United States
- Volunteers
- 48 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Allografts, Oral cGVHD
The Oral cGVHD as a Predictive Factor of Graft Versus Leukaemia Effect in Patients Who Received an Allograft
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the standard treatment for many malignant blood disorders. Its effectiveness is based on the graft-versus-leukemia (GVL) effect, which is intrinsically linked to…
- Trial name
- NCT07271498
- Testing
- Evaluation of oral cGVHD
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)
Managed Access Programs for INC424, Ruxolitinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Thrombocythemia Myelofibrosis (PET-MF), Severe/Very Severe COVID-19 Illness
- Trial name
- NCT04745637
- Testing
- Ruxolitinib
- Sponsor
- Novartis Pharmaceuticals
cGVHD
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2
This study is a single-arm, open-label, dose-escalation clinical trial to evaluate the safety, tolerability, changes and persistence of peripheral blood Treg cells, and pharmacodynamic characteristics of donor-derived Treg cell…
- Trial name
- NCT06920199
- Testing
- Donor-derived Treg cell injection combined with interleukin 2
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
cGvHD
A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.
- Trial name
- NCT06186804
- Testing
- ABSK021
- Where
- 14 sites in China
- Volunteers
- 64 people
- Sponsor
- Abbisko Therapeutics Co, Ltd